James Thommes

1.3k total citations
32 papers, 1.0k citations indexed

About

James Thommes is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, James Thommes has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 13 papers in Epidemiology and 8 papers in Infectious Diseases. Recurrent topics in James Thommes's work include Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). James Thommes is often cited by papers focused on Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). James Thommes collaborates with scholars based in United States, Switzerland and United Kingdom. James Thommes's co-authors include Bruce J. Dezube, Donald W. Northfelt, Richard D. Mamelok, Alvin E. Friedman‐Kien, David H. Henry, Charles Du Mond, Lawrence D. Kaplan, Margaret A. Fischl, Bárbara Miller and Susan E. Krown and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

James Thommes

32 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Thommes United States 13 390 276 231 210 180 32 1.0k
Christoph Fiehn Germany 26 204 0.5× 261 0.9× 212 0.9× 131 0.6× 252 1.4× 106 2.7k
A Ríos United States 8 495 1.3× 162 0.6× 57 0.2× 89 0.4× 247 1.4× 14 1.2k
J. Andrew Bradley United Kingdom 22 632 1.6× 292 1.1× 177 0.8× 28 0.1× 268 1.5× 50 2.0k
Florin Zaharie Romania 15 281 0.7× 138 0.5× 80 0.3× 50 0.2× 131 0.7× 71 989
Hatem Boulahdour France 17 88 0.2× 104 0.4× 192 0.8× 54 0.3× 159 0.9× 62 1.1k
Dong Zheng China 15 204 0.5× 205 0.7× 244 1.1× 47 0.2× 71 0.4× 49 1.1k
Soon Man Yoon South Korea 22 469 1.2× 363 1.3× 58 0.3× 63 0.3× 81 0.5× 85 1.4k
Qiuji Wu China 22 558 1.4× 103 0.4× 36 0.2× 128 0.6× 160 0.9× 109 1.6k
Young Chul Kim South Korea 20 441 1.1× 207 0.8× 136 0.6× 17 0.1× 41 0.2× 88 1.3k
Valentina Giudice Italy 22 258 0.7× 109 0.4× 41 0.2× 34 0.2× 107 0.6× 113 1.5k

Countries citing papers authored by James Thommes

Since Specialization
Citations

This map shows the geographic impact of James Thommes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Thommes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Thommes more than expected).

Fields of papers citing papers by James Thommes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Thommes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Thommes. The network helps show where James Thommes may publish in the future.

Co-authorship network of co-authors of James Thommes

This figure shows the co-authorship network connecting the top 25 collaborators of James Thommes. A scholar is included among the top collaborators of James Thommes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Thommes. James Thommes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peyrin‐Biroulet, Laurent, Brian G. Feagan, John Mansfield, et al.. (2017). Etrolizumab Treatment Leads to Early Improvement in Symptoms and Inflammatory Biomarkers in Anti-TNF-refractory Patients in the Open-Label Induction Cohort of the Phase 3 Hickory Study. Gastroenterology. 152(5). S603–S603. 4 indexed citations
2.
3.
Gane, Edward, Roman Rouzier, Tarek Hassanein, et al.. (2016). Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatology International. 10(3). 478–487. 5 indexed citations
4.
5.
6.
Bernaards, Coen, Rohit Kulkarni, Ethan R. Badman, et al.. (2014). Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP‐C and PROPEL studies. British Journal of Clinical Pharmacology. 78(3). 533–542. 1 indexed citations
7.
Pockros, Paul J., Donald M. Jensen, Naoky Tsai, et al.. (2013). JUMP-C: A Randomized Trial of Mericitabine Plus Pegylated Interferon Alpha-2a/Ribavirin for 24 Weeks in Treatment-NaÏVe HCV Genotype 1/4 Patients. Hepatology. 58(2). 514–523. 44 indexed citations
8.
Wedemeyer, Heiner, Donald M. Jensen, Robert Herring, et al.. (2013). Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a/Ribavirin Therapy in Treatment-NaïVe HCV Genotype 1/4 Patients. Hepatology. 58(2). 524–537. 36 indexed citations
9.
Pockros, Paul J., Dorte Møller Jensen, Renea A. Taylor, et al.. (2012). 1205 SVR-12 AMONG G1/4 TREATMENT-NAIVE PATIENTS RECEIVING MERICITABINE IN COMBINATION WITH PEG-IFNa-2A/RBV: INTERIM ANALYSIS FROM THE JUMP-C STUDY. Journal of Hepatology. 56. S477–S478. 12 indexed citations
10.
Reddy, K. Rajender, Mitchell L. Shiffman, M. Rodríguez‐Torres, et al.. (2010). Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads. Gastroenterology. 139(6). 1972–1983. 25 indexed citations
11.
Cheng, Wendy, Stuart K. Roberts, Geoffrey W. McCaughan, et al.. (2010). Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology. 53(4). 616–623. 36 indexed citations
12.
Asselah, Tarik, Laurent Essioux, Patrick Marcellin, et al.. (2010). 1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN. Journal of Hepatology. 52. S456–S456. 14 indexed citations
13.
Rockstroh, Jürgen K., Edwin DeJesus, Cynthia Wat, et al.. (2008). Adherence to Enfuvirtide and Its Impact on Treatment Efficacy. AIDS Research and Human Retroviruses. 24(2). 141–148. 4 indexed citations
14.
Gottlieb, Michael, et al.. (2008). Safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection. Antiviral Therapy. 13(5). 723–727. 5 indexed citations
15.
Shalit, Peter, et al.. (2007). Quality of Life and Tolerability After Administration of Enfuvirtide with a Thin-Walled Needle: QUALITÉ Study. HIV Clinical Trials. 8(1). 24–35. 14 indexed citations
16.
Melby, Thomas, Ralph DeMasi, Gabrielle Heilek, et al.. (2007). Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS. 21(18). 2537–2539. 20 indexed citations
17.
Aboulafia, David M., David H. Henry, Ronald J. Grossman, et al.. (2003). 9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma. Archives of Dermatology. 139(2). 178–86. 38 indexed citations
18.
Northfelt, Donald W., Bruce J. Dezube, James Thommes, et al.. (1998). Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.. Journal of Clinical Oncology. 16(7). 2445–2451. 485 indexed citations
19.
Northfelt, Donald W., Bruce J. Dezube, James Thommes, et al.. (1997). Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.. Journal of Clinical Oncology. 15(2). 653–659. 129 indexed citations
20.
Rowland, David L., et al.. (1980). Comparison of androgenic effects on food intake and body weight in adult rats. Physiology & Behavior. 24(2). 205–209. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christoph Fiehn Breakdown of academic impact, for papers by A Ríos Breakdown of academic impact, for papers by J. Andrew Bradley Breakdown of academic impact, for papers by Florin Zaharie Breakdown of academic impact, for papers by Hatem Boulahdour Breakdown of academic impact, for papers by Dong Zheng Breakdown of academic impact, for papers by Soon Man Yoon Breakdown of academic impact, for papers by Qiuji Wu Breakdown of academic impact, for papers by Young Chul Kim Breakdown of academic impact, for papers by Valentina Giudice
Rankless by CCL
2026